Departments with Active Clinical Trials
Anesthesiology
| Study Title |
Principal Investigator |
Clinical Area |
Contact Number |
| A Single Arm, Open Label Study to Compare the Pharmacokinetics, Safety, Efficacy of SPRIX® (intranasal ketorolac tromethamine) in 12 to 17 Year-Old Patients vs. Adult Patients (18-64 Years) Undergoing Open Surgical Procedures |
Ashish Sinha M.D. |
Anesthesiology |
215.762.7922 |
| A Phase II, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function in Patients Following Small or Large Bowel Resection with Primary Anastomosis |
Ashish Sinha M.D. |
Anesthesiology |
215.762.7922 |
| Caldolor versus Caldolor Plus OFIRMEV in Total Knee or Hip Arthroplasty Surgeries: A Single Center, Randomized, Open-Label Trial to Compare the Safety and Efficacy of Caldolor Used Singly and in Combination with Ofirmev in Total Knee or Hip Arthroplasty Surgery Patients |
Anita Gupta M.D. |
Anesthesiology |
215.762.7922 |
Back to Top
Biomedical Engineering
| Study Title |
Principal Investigator |
Clinical Area |
Contact Number |
| Prospective Registry of Mammaprint in Breast Cancer Patients with an Intermediate Recurrence Score (PROMIS) |
Ari D. Brooks M.D. |
Surgery |
215.762.4157 |
Back to Top
CNHP - Physician's Assistant
| Study Title |
Principal Investigator |
Clinical Area |
Contact Number |
| A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients with Clostridium difficile Associated Diarrhea |
James C. Reynolds M.D. |
Gastroenterology |
215.762.8397 |
Back to Top
Medicine
| Study Title |
Principal Investigator |
Clinical Area |
Contact Number |
| Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema |
Eric P. Stander M.D. |
Emergency Medicine |
215.762.8397 |
| Closure of Atrial Septal Defects with the AMPLATZER® Septal Occluder Post Approval Study (ASD PMS II) |
William G. Kussmaul III M.D. |
Cardiology |
215.762.8397 |
| XIENCE V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study (Protocol 06-374) |
William G. Kussmaul III M.D. |
Cardiology |
215.762.8397 |
| A Randomized, Double-Blind, Parallel Group, Multicenter Phase IIIb Study to Compare Ticagrelor with Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischaemic Stroke in Patients with Established Peripheral Artery Disease EUCLID (Examining Use of tiCagreLor In paD) |
Gary S. Ledley M.D. |
Cardiology |
215.762.8397 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment with Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome (Study Number EFC11319) (Compound: Lixisenatide/AVE0010) (IND # 62,724) |
Gary S. Ledley M.D. |
Cardiology |
215.762.8397 |
| Phase 3 Multi Center DB, Randomized Pcb Controlled Study of the Effects of Once Daily Doses of 75 Mg Azimilide DiHydrochloride on the Incidence of Cardiovascular Hospitalizations/ER Department Visits or Cardiovascular Deaths in Pts. With an ICD |
Steven P. Kutalek M.D. |
Cardiology |
215.762.8397 |
| Late Sodium Current Blockade in High-Risk ICD Patients Ranolazine ICD Trial (RAID) |
Steven P. Kutalek M.D. |
Cardiology |
215.762.8397 |
| Echocardiography Guided Cardiac Resynchronization Therapy (Echo CRT) |
Steven P. Kutalek M.D. |
Cardiology |
215.762.8397 |
| Does RV Pacing to Restore Right Ventricular Synchrony Improve Hemodynamics in Patients with Right Bundle Branch Block (RBBB) and Moderate to Severe Pulmonary Arterial Hypertension (PAH) |
Steven P. Kutalek M.D. |
Cardiology |
215.762.8397 |
| Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA Trial) |
Steven P. Kutalek M.D. |
Cardiology |
215.762.8397 |
| The IMPACT of BIOTRONIK Home Monitoring Guided Anticoagulation on Stroke Risk in Patients with ICD and CRT-D Devices |
Steven P. Kutalek M.D. |
Cardiology |
215.762.8397 |
| Block HF Biventricular Versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (Protocol # BLOCK HF 6 Dec 2005) (IDE # G030156/S1) |
Steven P. Kutalek M.D. |
Cardiology |
215.762.8397 |
| S-ICD System Clinical Investigation |
Steven P. Kutalek M.D. |
Cardiology |
215.762.8397 |
| Clinical Evaluation of the Physiological Diagnosis Function in the Paradym CRT Device - CLEPSYDRA Protocol |
Steven P. Kutalek M.D. |
Cardiology |
215.762.8397 |
| Longitudinal Surveillance Registry of the ACUITY Sprial Lead - LSR of the Acuity Spiral |
Steven P. Kutalek M.D. |
Cardiology |
215.762.8397 |
| Medtronic - Attain StarFix R 4195 Extraction Study |
Steven P. Kutalek M.D. |
Cardiology |
215.762.8397 |
| Ovatio CRT and Situs OTW LV Lead Post Approval Study (Ovatio CRT PAS) |
Steven P. Kutalek M.D. |
Cardiology |
215.762.8397 |
| St. Jude Medical Product Longevity and Performance (SCORE) Registry |
Steven P. Kutalek M.D. |
Cardiology |
215.762.8397 |
| Registry of AT/AF Episodes in the CRM Device Population: RATE Registry (Protocol # CD204 06 06-007 October 2006) |
Steven P. Kutalek M.D. |
Cardiology |
215.762.8397 |
| St. Jude Medical Cardiac Lead Assessment Study |
Steven P. Kutalek M.D. |
Cardiology |
215.762.8397 |
| ISIS-ICD Inappropriate Shock Reduction with PARAD+ Rhythm Discrimination |
Steven P. Kutalek M.D. |
Cardiology |
215.762.8397 |
| BOCEPREVIR IN COMMUNITY PRACTICE: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Educational Program |
Kenneth D. Rothstein M.D. |
Hepatology |
215.762.8397 |
| Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery |
Kenneth D. Rothstein M.D. |
Hepatology |
215.762.8397 |
| A Phase III Study of Chemotherapy and Chemoradiotherapy with or without Hyperacute®-Pancreas (Algenpantucel-L) Immunotherapy in Subjects with Surgically Resected Pancreatic Cancer |
Rene R. Rubin M.D. |
Hematology / Oncology |
215.762.8397 |
| CVRx North American Resistant Hypertension Monitoring Study |
Howard J. Eisen M.D. |
Cardiology |
215.762.8397 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome (SYR-322 402) |
Howard J. Eisen M.D. |
Cardiology |
215.762.8397 |
| Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure with Challenging Volume Management |
Howard J. Eisen M.D. |
Cardiology |
215.762.8397 |
| A Multicenter, Randomized, Double-Blind, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients with Chronic Heart Failure and Reduced Ejection Fraction |
Howard J. Eisen M.D. |
Cardiology |
215.762.8397 |
| A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus |
Howard J. Eisen M.D. |
Cardiology |
215.762.8397 |
| Heartsbreath Test for Heart Transplant Rejection |
Howard J. Eisen M.D. |
Cardiology |
215.762.8397 |
| INDICATE HF Integrated Diagnostics Can Aiter Heart Failure |
Howard J. Eisen M.D. |
Cardiology |
215.762.8397 |
| COMPASS-HF (Chronicle® Studies including Chronicle Phase I/II, Pulmonary Artery Hypertension (PAH) Pilot, COMPASS-HF, and REDUCEhf |
Howard J. Eisen M.D. |
Cardiology |
215.762.8397 |
| Benefit Study: Risk Stratification & Benefits with CRT Therapy |
Howard J. Eisen M.D. |
Cardiology |
215.762.8397 |
| A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the 6 months efficacy and safety to aliskiren therapy on top of standard therapy, on morbidity and mortality when initiated early after hospitalization of acute decompensated heart failure |
Howard J. Eisen M.D. |
Cardiology |
215.762.8397 |
| A Phase II, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of PROCHYMAL® (ex vivo cultured adult human mesenchymal stem cells) intravenous infusion following acute myocardial infarction |
Howard J. Eisen M.D. |
Cardiology |
215.762.8397 |
| A Faciliatated Access Program to Provide Everolimus for Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplants (Final IV 12-Aug-2003) (Amendment No. 2 Release Date April 2005) (Investigators' Brochure Final 2-Jun-03) (Investigators' Brochure Appendix 1 2-Jun-03) |
Howard J. Eisen M.D. |
Cardiology |
215.762.8397 |
| AVOID-HF: Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure |
Howard J. Eisen M.D. |
Cardiology |
215.762.8397 |
| A Prospective Randomized Double Blinded Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients with Acute Myocardial Infarction |
Howard J. Eisen M.D. |
Cardiology |
215.762.8397 |
| A Phase 3b, Multicenter, Randomized, Single-Blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA® (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized with Dilutional Hyponatremia |
Shelley R. Hankins M.D. |
Cardiology |
215.762.8397 |
| TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone and Tagonist) |
Howard J. Eisen M.D. |
Cardiology |
215.762.8397 |
| A Pilots Study of Immune Activation and Drug Absorption in HIV-Infected Patients |
Christopher Vinnard M.D. |
Infectious Diseases |
215.762.8397 |
| A Phase I, Open Label, Dual Cohort, Single Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Autologous CD4 T Cells Modified with a Retroviral Vector Expressing the MazF Endoribonuclease Gene in Patients with HIV |
Jeffrey M. Jacobson M.D. |
Infectious Diseases |
215.762.8397 |
| A Randomized, Double Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption |
Jeffrey M. Jacobson M.D. |
Infectious Diseases |
215.762.8397 |
| Connect CLL: The Chronic Lymphocytic Leukemia Disease Registry |
Kristine M. Ward M.D. |
Hematology / Oncology |
215.762.8397 |
| Prospective Study to Investigate the Relationship Between Physician-Assessed Febrile Neutopenia (FN) Risk Probability Score and Prediction Tool FN Risk Probability Score for Patients with Non-Myeloid Malignancies |
Kristine M. Ward M.D. |
Hematology / Oncology |
215.762.8397 |
| A Phase III Randomized, Placebo-Controlled, Clinical Trail to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy |
Michael J. Styler M.D. |
Hematology / Oncology |
215.762.8397 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500 ug Once-Every-3-Weeks in Anemic Subjects with Advanced Stage Non-Small Cell Lung Cancer Receiving Multi-Cycle Chemotherapy (Protocol Number: 20070782; Date: 25 May 2010) (BB-IND 8223) |
Kristine M. Ward M.D. |
Hematology / Oncology |
215.762.8397 |
| Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogencity of V212/Inactivated Varicella-Zoster Virus (VZV) Vaccine in Recipients of Autologous Hematopoitic Cell Transplants (HCTs) |
Michael J. Styler M.D. |
Hematology / Oncology |
215.762.8397 |
| Phase 2, Multi-Center, Randomized, Double-Blind, Parallel-Group Study of the Safety and Efficacy of Different Lenalidomide (Revlimid) Dose Regimens in Subjects with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia CC-5013=CLL-009 |
Michael J. Styler M.D. |
Hematology / Oncology |
215.762.8397 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients with Diabetic Kidney Disease |
Jesse M. Goldman M.D. |
Nephrology |
215.762.8397 |
| START-CKD: Strategies Using Darbepoetin alfa to Avoid Transfusions in Chronic Kidney Disease |
Jesse M. Goldman M.D. |
Nephrology |
215.762.8397 |
| A Multicenter Prospective Cohort Study to Investigate if Ganciclovir Significantly Affects Spermatogenesis in Adult Male Renal Transplant Recipients Receiving up to 200 Days Valganciclovir vs. Concurrent Untreated Matched Controls |
Alden Doyle M.D. |
Nephrology |
215.762.8397 |
| A Phase 2, Multicenter, Open-Label, Active Comparator-Controlled, Extension Trial to Evaluate the Long-Term Safety and Efficacy of CP-690,550 in Renal Allograft Recipients |
Karthik M. Ranganna M.D. |
Nephrology |
215.762.8397 |
| Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) (Protocol No.: 402-C-0903) |
Ziauddin Ahmed M.D. |
Nephrology |
215.762.8397 |
| Coronary Obstruction Detection by Molecular Personalized Gene Expression (COMPASS) Study (CDX 000007) |
Diwakar Jain M.D. |
|
215.762.8397 |
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study of KB001-A in Subjects with Cystic Fibrosis Infected with Pseudomonas aeruginosa |
Jeffrey B. Hoag M.D. |
Pulmonology |
215.762.8397 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Subjects with Cystic Fibrosis |
Michael J. Stephen M.D. |
Pulmonology |
215.762.8397 |
| A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors |
Michael J. Stephen M.D. |
Pulmonology |
215.762.8397 |
| Cephalon C38072/3084: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients with Moderate to Severe Asthma |
Edward S. Schulman M.D. |
Pulmonology |
215.762.8397 |
| A Prospective, 5-Year Registry Study to Monitor the Susceptibility to Aztreonam of Pseudomonas aeruginosa (PA) Isolates from Patients with Cystic Fibrosis in the United States [AIR-CF5] |
Jeffrey B. Hoag M.D. |
Pulmonology |
215.762.8397 |
| A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MP-376 (Levofloxacin Inhallation Solution, Aeroquin¿) in Stable Cystic Fibrosis Patients (Study Number: MPEX-207) |
Jeffrey B. Hoag M.D. |
Pulmonology |
215.762.8397 |
| A Phase III International, Randomized, Double-Blind, Double-Dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents with Influenza |
Michael Sherman M.D. |
Pulmonology |
215.762.8397 |
| A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects with non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX1) |
Michael Sherman M.D. |
Pulmonology |
215.762.8397 |
Back to Top
Neurology
| Study Title |
Principal Investigator |
Clinical Area |
Contact Number |
| A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients with Amyotrophic Lateral Sclerosis (ALS) |
Terry D. Heiman-Patterson M.D. |
Neurology |
215.762.8397 |
| A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis |
David S. Tabby D.O. |
Neurology |
215.762.8397 |
| Multi-centre, randomized, double-blind, placebo-controlled, parallel-group, 9 month, equivalence trial comparing the efficacy and safety and tolerability of GTR (Synthon BV) to Copaxone® (Teva) in subjects with relapsing remitting multiple sclerosis followed by an open-label 15 month GTR treatment part evaluating the long-term GTR treatment effects |
David S. Tabby D.O. |
Neurology |
215.762.8397 |
| A 12-Month, Prospective, Randomized, Active-Controlled, Open-Label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-Line Disease Modifying Therapies in Adults who are in Early Stages of Treatment for Relapsing Remitting Multiple Sclerosis |
David S. Tabby D.O. |
Neurology |
215.762.8397 |
| An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects with Amyotrophic Lateral Sclerosis |
Terry D. Heiman-Patterson M.D. |
Neurology |
215.762.8397 |
| JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri: STRATIFY-2 |
David S. Tabby D.O. |
Neurology |
215.762.8397 |
| A Multi-center Double-Blind Parallel-Group Placebo-Controlled Study of the Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis (Protocol EFC10531) |
David S. Tabby D.O. |
Neurology |
215.762.8397 |
| A Multicenter, Open-Label Extension Trial to Assess the Long-Term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-Onset Seizures |
Jyoti A. Pillai M.D. |
Neurology |
215.762.8397 |
| A Historical-Controlled, Multicenter, Double-Blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400mg/day Monotherapy in Subjects with Partial-Onset Seizures (Protocol SP902) |
Jyoti A. Pillai M.D. |
Neurology |
215.762.8397 |
| Long-Term Eslicarbazepine Acetate Extension Study |
Jyoti A. Pillai M.D. |
Neurology |
215.762.8397 |
| A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumad (AAB-001, ELN115727) in Subjects with Alzheimer's Disease who Participated in Study ELN115727-301 or in Study ELN115727-302 |
Carol F. Lippa M.D. |
Neurology |
215.762.8397 |
| A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Patients with Mild to Moderate Alzheimer's Disease Who are Apolipoprotein E4 Non-Carriers (ELN115727-301) |
Carol F. Lippa M.D. |
Neurology |
215.762.8397 |
| A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients with Amyothrophic Lateral Sclerosis (ALS) |
Terry D. Heiman-Patterson M.D. |
Neurology |
215.762.8397 |
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects wih Amyotrophic Lateral Sclerosis |
Terry D. Heiman-Patterson M.D. |
Neurology |
215.762.8397 |
| A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients with Generalized Myasthenia Gravis on Standard Therapy |
Anahita F. Deboo M.D. |
Neurology |
215.762.8397 |
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects with Mild to Moderate Alzheimer's Disease |
Carol F. Lippa M.D. |
Neurology |
215.762.8397 |
| A Phase 2 Study of Human Placenta Derived Cells [PDA-001 (cenplacel-L] in Patients with Complex Regional Pain Syndrome |
Robert J. Schwartzman M.D. |
Neurology |
215.762.8397 |
| Long-Term, Prospective, Observational, Multinational, Parallel-Cohort Study Monitoring Safety in Patients with MS Newly Started with Fingolimod Once Daily or Treated with Another Approved Disease-Modifying Therapy |
David S. Tabby D.O. |
Neurology |
215.762.8397 |
| PRISM - The Pseudobulbar Affect Registry Series |
David S. Tabby D.O. |
Neurology |
215.762.8397 |
| A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Four-Arm, Multicenter, Dose-Finding Study to Assess the Safety and Efficacy of Three Dose Leves of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis |
David S. Tabby D.O. |
Neurology |
215.762.8397 |
Back to Top
Obstetrics & Gynecology
| Study Title |
Principal Investigator |
Clinical Area |
Contact Number |
| Microbiology and immunology of recurrent or chronic vaginosis and vaginitis |
Paul Nyirjesy M.D. |
Obstetrics & Gynecology |
215.762.1720 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated Pain |
Carl R. DellaBadia M.D. |
Obstetrics & Gynecology |
215.762.1720 |
| A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis |
Paul Nyirjesy M.D. |
Obstetrics & Gynecology |
215.762.1720 |
| The GDM Follow-Up Study |
Lauren A. Plante M.D. |
Obstetrics & Gynecology |
215.762.1720 |
| A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) |
Lauren A. Plante M.D. |
Obstetrics & Gynecology |
215.762.1720 |
| A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Fluconazole versus Fluconazole and MGCD290 for the Treatment of Moderate to Severe Acute Vulvovaginal Candidiasis |
Paul Nyirjesy M.D. |
Obstetrics & Gynecology |
215.762.1720 |
| A Phase 2a Proof of Concept Study to Evaluate the Safety and Efficacy of Elagolix in Pre-Menopausal Women with Heavy Uterine Bleeding and Uterine Fibroids |
Carl R. DellaBadia M.D. |
Obstetrics & Gynecology |
215.762.1720 |
| Battery Powered bion(R) Clinical Investigation bion (R) - An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urgency-Frequency Syndrome |
Kristene E. Witmore M.D. |
Obstetrics & Gynecology |
215.762.1720 |
| Social Problem Solving and Psychological Distress Among Pregnant Women |
Arthur M. Nezu M.D. |
Obstetrics & Gynecology |
215.762.1720 |
| Reducing Cardiovascular Risk: Internet and In-Person Acceptance-Based Approaches |
Arthur M. Nezu M.D. |
Obstetrics & Gynecology |
215.762.1720 |
Back to Top
Radiation Oncology
| Study Title |
Principal Investigator |
Clinical Area |
Contact Number |
| A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer |
Lydia T. Konarnicky-Kocher M.D. |
Radiation Oncology |
215.762.4984 |
| Carotid Stenting for High Surgical Risk Patients; Evaluating Outcomes Through the Collection of Clinical Evidence ("CHOICE") / Protocol No. 06-717 |
Robert A. Koenigsberg M.D. |
Radiation Oncology |
215.762.4984 |
| Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterectomy-Sapphire WW (P06-3603) |
Robert A. Koenigsberg M.D. |
Radiation Oncology |
215.762.4984 |
| CANOPY - Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy |
Robert A. Koenigsberg M.D. |
Radiation Oncology |
215.762.4984 |
| The Gore FREEDOM Study: GORE Flow Reversal System Extension Study for the Ongoing Collection of Patient Outcomes |
Robert A. Koenigsberg M.D. |
Radiation Oncology |
215.762.4984 |
| Validation of Non-Invasive Blood Pressure Device |
Neal B. Handly M.D. |
Radiation Oncology |
215.762.4984 |
Back to Top
Surgery
| Study Title |
Principal Investigator |
Clinical Area |
Contact Number |
| A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD® in Subjects with Alcohol Induced Liver Decompensation (AILD) |
David J. Reich M.D. |
Surgery |
215.762.4157 |
| A Prospective, Single-Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI) |
David E. Stein M.D. |
Surgery |
215.762.4157 |
| A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients with Complicated Intra-Abdominal Infection (cIAI) |
Andres E. Castellanos M.D. |
Surgery |
215.762.4157 |
| A Phase 2/3, Double-Blind, Placebo-Controlled, Two-Part Study (Part 1 Open-Label) to Assess the Safety, Efficacy and Pharmacokinetics of Single Intravenous Doses of ASP8597 (Diannexin) in de novo Kidney Transplant Recipient |
David J. Reich M.D. |
Surgery |
215.762.4157 |
| Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial - Protocol # IM103008 (IND BB 9418) |
David J. Reich M.D. |
Surgery |
215.762.4157 |
| A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Locally Recurrent Prostate Cancer with HIFU |
Laurence H. Belkoff M.D. |
Surgery |
215.762.4157 |
| The Zen Study: The Medtronic Zotarolimus-Eluting Peripheral Stent System for the Treatment of Erectile Dysfunction in Males with Sub-Optimal Response to PDE5 Inhibitors |
Laurence H. Belkoff M.D. |
Surgery |
215.762.4157 |
| A Randomized, Open Label, Parallel-Group, Multi-Center Trial to Compare the Efficacy and Safety of TachoSil® versus Standard Hemostatic Fleece Material for the Secondary Treatment of Local Bleeding in Hepatic Resection Surgery |
Gary Sheng-Guang Xiao M.D. |
Surgery |
215.762.4157 |
| An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients Hospitalized with Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments and the Impact on Resource Utilization |
Gregory Malat M.D. |
Surgery |
215.762.4157 |
| A Phase IV, Multi-Center, Prospective, Observational Study of the Safety, Effectiveness and Tolerability of Immunosuppressant Regimens to Treat Renal Transplant Patients in Routine Clinical Practice (CERL080A-US40) |
Gregory Malat M.D. |
Surgery |
215.762.4157 |
| Piezo Electric Finger (PEF) Protocol - Portable, Low Cost Breast Cancer Detector |
Ari D. Brooks M.D. |
Surgery |
215.762.4157 |
| Follow-Up Study of Breast Health Outcomes and Selected Biomarkers in Women at High Risk for Breast Cancer: The Serial Evaluation of Ductal Epithelium (SEDE) Clinical Trial |
Ari D. Brooks M.D. |
Surgery |
215.762.4157 |
| A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) versus Placebo Plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed Prior Systemic Therapy |
Gary Sheng-Guang Xiao M.D. |
Surgery |
215.762.4157 |
| A Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 with Lucassin® (Terlipressin) (Reverse) |
David A. Sass M.D. |
Surgery |
215.762.4157 |
Back to Top
|